What is Zacks Research’s Estimate for IRWD Q4 Earnings?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Research analysts at Zacks Research boosted their Q4 2026 EPS estimates for shares of Ironwood Pharmaceuticals in a research note issued on Tuesday, January 20th. Zacks Research analyst Team now anticipates that the biotechnology company will post earnings per share of $0.23 for the quarter, up from their prior estimate of $0.16. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q3 2027 earnings at ($0.01) EPS.

IRWD has been the subject of a number of other research reports. Weiss Ratings restated a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, December 29th. Citizens Jmp upgraded Ironwood Pharmaceuticals from a “market perform” rating to a “market outperform” rating and set a $8.00 target price on the stock in a research note on Monday, January 5th. Wells Fargo & Company upped their price target on shares of Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the stock an “equal weight” rating in a research report on Monday, January 5th. Craig Hallum raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, January 5th. Finally, Citigroup upgraded shares of Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Monday, January 5th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $5.74.

Ironwood Pharmaceuticals Trading Up 15.9%

NASDAQ:IRWD opened at $5.31 on Wednesday. The stock has a 50 day moving average of $3.69 and a 200-day moving average of $2.13. The firm has a market capitalization of $863.83 million, a PE ratio of 33.19 and a beta of 0.18. Ironwood Pharmaceuticals has a 52 week low of $0.53 and a 52 week high of $5.78.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Monday, November 10th. The biotechnology company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.15. Ironwood Pharmaceuticals had a net margin of 8.70% and a negative return on equity of 15.17%. The firm had revenue of $122.06 million for the quarter, compared to analyst estimates of $74.22 million.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. OVERSEA CHINESE BANKING Corp Ltd bought a new stake in shares of Ironwood Pharmaceuticals in the 2nd quarter worth $25,000. Integrated Wealth Concepts LLC grew its holdings in Ironwood Pharmaceuticals by 21.4% during the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 3,406 shares during the period. R Squared Ltd raised its position in Ironwood Pharmaceuticals by 286.5% in the second quarter. R Squared Ltd now owns 38,765 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 28,735 shares in the last quarter. Focus Partners Advisor Solutions LLC lifted its holdings in Ironwood Pharmaceuticals by 284.6% in the 2nd quarter. Focus Partners Advisor Solutions LLC now owns 39,743 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 29,409 shares during the last quarter. Finally, Captrust Financial Advisors acquired a new stake in Ironwood Pharmaceuticals in the 2nd quarter valued at about $32,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.